“An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris” (2019) SKIN The Journal of Cutaneous Medicine, 3, p. S1. doi:10.25251/skin.3.supp.1.